Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nada Alsuhebany, Congshan Pan, Eileen Holovac, Brian Do & Ali McBride. (2023) Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review. Blood and Lymphatic Cancer: Targets and Therapy 13, pages 67-76.
Read now
Read now
Bilal Tariq, Ying C. Ou, Jennifer C. Stern, Vaibhav Mundra, Nicole Wong Doo, Patricia Walker, Katharine L. Lewis, Chester Lin, William Novotny, Srikumar Sahasranaman & Stephen Opat. (2023) A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia & Lymphoma 64:2, pages 329-338.
Read now
Read now
Shayna Sarosiek, David Sermer, Andrew R. Branagan, Steven P. Treon & Jorge J. Castillo. (2022) Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy 22:5, pages 471-478.
Read now
Read now
Constantine S. Tam, Ying C. Ou, Judith Trotman & Stephen Opat. (2021) Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib. Expert Review of Clinical Pharmacology 14:11, pages 1329-1344.
Read now
Read now
Articles from other publishers (8)
Clement Chung, Godsfavour Umoru, Karen Abboud & Eleanor Hobaugh. (2023)
Sequencing and combination of current
small‐molecule
inhibitors for chronic lymphocytic leukemia: Where is the evidence?
. European Journal of Haematology.
Crossref
Crossref
Jennifer R. BrownBarbara EichhorstPeter HillmenWojciech JurczakMaciej KaźmierczakNicole LamannaSusan M. O’BrienConstantine S. TamLugui QiuKeshu ZhouMartin SimkovicJiri MayerAmanda Gillespie-TwardyAlessandra FerrajoliPeter S. GanlyRobert WeinkoveSebastian GrosickiAndrzej MitalTadeusz RobakAnders OsterborgHabte A. YimerTommi SalmiMegan-Der-Yu WangLina FuJessica LiKenneth WuAileen CohenMazyar Shadman. (2023) Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine 388:4, pages 319-332.
Crossref
Crossref
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Syed F Zafar, Jamal Misleh, Edwin C Kingsley, Habte A Yimer, Benjamin Freeman, Subramanya S Rao, Arvind Chaudhry, Praveen K Tumula, Mitul D Gandhi, Sudhir Manda, Dih-Yih Chen, Kunthel By, Linlin Xu, Ye Liu, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Jane Huang & Jeff P Sharman. (2023) Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. The Lancet Haematology 10:1, pages e35-e45.
Crossref
Crossref
Michael Arustamyan, Pavel Kibrik, Dilara Hatipoglu, Brandon Bungo, Amgad Mentias, Brian T. Hill & Rohit Moudgil. (2022) The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review. European Journal of Haematology 109:6, pages 696-710.
Crossref
Crossref
Wei Xu, Shenmiao Yang, Constantine S. Tam, John F. Seymour, Keshu Zhou, Stephen Opat, Lugui Qiu, Mingyuan Sun, Tingyu Wang, Judith Trotman, Ling Pan, Sujun Gao, Jianfeng Zhou, Daobin Zhou, Jun Zhu, Yuqin Song, Jianda Hu, Ru Feng, Haiwen Huang, Dan Su, Miao Shi & Jianyong Li. (2022) Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Advances in Therapy 39:9, pages 4250-4265.
Crossref
Crossref
Yuqin Song, Mingyuan Sun, Junyuan Qi, Wei Xu, Jianfeng Zhou, Dengju Li, Jianyong Li, Lugui Qiu, Chenmu Du, Haiyi Guo, Jane Huang, Zhiyu Tang, Ying Ou, Binghao Wu, Yiling Yu & Jun Zhu. (2022)
A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective
Bruton tyrosine kinase
inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
. British Journal of Haematology 198:1, pages 62-72.
Crossref
Crossref
Juswinder Singh. (2022) The Ascension of Targeted Covalent Inhibitors. Journal of Medicinal Chemistry 65:8, pages 5886-5901.
Crossref
Crossref
Javier Muñoz, Yucai Wang, Preetesh Jain & Michael Wang. (2022) Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Therapeutic Advances in Hematology 13, pages 204062072210939.
Crossref
Crossref